Chugin Infinity Fund No. 3 Makes Additional Investment in xCARE Inc.
Key facts
- Chugin Infinity Fund No. 3 Makes Additional Investment in xCARE Inc.
- Chugin Capital Partners has made an additional investment in xCARE, a specialized expert platform for the medical industry, through the Chugin Infinity Fund No. 3 during its Series A round. xCARE provides a matching service utilizing an expert network and AI to address talent shortages in pharmaceutical and medical device development, aiming for further business expansion with this funding.
- Source: PR Times
- Date: June 12, 2026
Direct answer
Chugin Capital Partners has made an additional investment in xCARE, a specialized expert platform for the medical industry, through the Chugin Infinity Fund No. 3 during its Series A round. xCARE provides a matching service utilizing an expert network and AI to address talent shortages in pharmaceutical and medical device development, aiming for further business expansion with this funding.
- Citation
- Chugin Infinity Fund No. 3 Makes Additional Investment in xCARE Inc. (June 12, 2026), PR Times
- Source
- PR Times
- Date
- June 12, 2026
Chugin Capital Partners has made an additional investment in xCARE, a specialized expert platform for the medical industry, through the Chugin Infinity Fund No. 3 during its Series A round. xCARE provides a matching service utilizing an expert network and AI to address talent shortages in pharmaceutical and medical device development, aiming for further business expansion with this funding.
📋 Article Processing Timeline
- 📰 Published: June 12, 2026 at 19:04
- 🔍 Collected: June 12, 2026 at 10:21
- 🤖 AI Analyzed: June 12, 2026 at 16:52 (6h 30m after Collected)
Chugin Capital Partners (Okayama City, Representative Director: Hiroyuki Okada) announced today that the "Chugin Infinity Fund No. 3," which invests in startups, has made an additional investment in xCARE Inc. (Crosscare, Shibuya-ku, Tokyo, Representative Director: Sho Fukunaga, hereinafter referred to as "xCARE") in a Series A round in May 2026, following its Pre-Series A round in January 2024.
xCARE operates "xCARE," a specialized expert platform for the medical industry, including pharmaceuticals and medical devices. It provides matching of expert personnel and project promotion support necessary for development projects to pharmaceutical companies, medical device manufacturers, bio-ventures, and academia, contributing to shortening product development timelines and increasing success rates.
In pharmaceutical and medical device development, highly specialized knowledge in areas such as regulatory affairs, clinical development, quality assurance, and business development is required. However, since the required expertise varies depending on the project, securing appropriate personnel as needed is a significant challenge.
To address this challenge, xCARE utilizes its network of over 2,000 experts, both domestically and internationally, to provide a system that allows for the utilization of "the right people, at the right time, in the right way." In recent years, overseas projects have also been increasing, and the company is expanding its business as a platform supporting global medical product development.
Furthermore, xCARE is developing an AI-powered matching function to improve the efficiency of expert search and proposal operations, aiming for faster and more accurate matching.
Going forward, xCARE is expected to further expand its expert network, develop overseas customers, and enhance its AI matching capabilities, thereby contributing to solving industry challenges through the establishment of a global expert platform in the medical field.
Our group will promote business development support for academia and medical-related companies, particularly in the Chushikoku region, through collaboration with xCARE, and will continue to work towards creating innovation in the medical field and further developing the local community.
1. Overview of Investment Project
Investee Name (Headquarters Location)
xCARE Inc. (Shibuya-ku, Tokyo)
Representative
Sho Fukunaga
Date of Establishment
January 31, 2022
Business Description
Building and supporting the execution of development projects on a specialized human resource platform for the pharmaceutical and medical device industries.
Homepage
Corporate: https://www.xcare-medical.com/campany/top/
Services: https://www.xcare-medical.com/
[Comment from Sho Fukunaga, CEO of xCARE Inc.]
I am deeply grateful for your continued support following the previous Pre-A round.
xCARE has grown into a platform with over 1,000 experts in Japan and over 1,000 overseas available for contract work, and many pharmaceutical and medical device manufacturers are utilizing these experts.
Our theme is to "change industry business practices." Previously, our industry had only two options: "hiring" or "full outsourcing." We aim to provide new options, such as incorporating contract workers as an alternative to hiring into our operations, allowing us to accumulate know-how and control while advancing highly fluid projects, or building operational structures for parts of organizational roles with contract workers.
Similar services (like SES) exist in other industries, including the IT industry. We also entrust contract workers with roles such as "marketing," "product development," and "inside sales." In particular, performance has dramatically improved by switching from outsourcing to contract workers for product development and inside sales. We want to expand this third new option in the pharmaceutical and medical device industry to companies that find "hiring risky," "uncertain about the future," or "unable to hire good talent," and contribute to the industry as a whole.
Chugin Financial Group, Inc.
Phone: 086-223-3110
Public Relations Center: Okajima (Ext. 2255)
Keywords:
xCARE operates "xCARE," a specialized expert platform for the medical industry, including pharmaceuticals and medical devices. It provides matching of expert personnel and project promotion support necessary for development projects to pharmaceutical companies, medical device manufacturers, bio-ventures, and academia, contributing to shortening product development timelines and increasing success rates.
In pharmaceutical and medical device development, highly specialized knowledge in areas such as regulatory affairs, clinical development, quality assurance, and business development is required. However, since the required expertise varies depending on the project, securing appropriate personnel as needed is a significant challenge.
To address this challenge, xCARE utilizes its network of over 2,000 experts, both domestically and internationally, to provide a system that allows for the utilization of "the right people, at the right time, in the right way." In recent years, overseas projects have also been increasing, and the company is expanding its business as a platform supporting global medical product development.
Furthermore, xCARE is developing an AI-powered matching function to improve the efficiency of expert search and proposal operations, aiming for faster and more accurate matching.
Going forward, xCARE is expected to further expand its expert network, develop overseas customers, and enhance its AI matching capabilities, thereby contributing to solving industry challenges through the establishment of a global expert platform in the medical field.
Our group will promote business development support for academia and medical-related companies, particularly in the Chushikoku region, through collaboration with xCARE, and will continue to work towards creating innovation in the medical field and further developing the local community.
1. Overview of Investment Project
Investee Name (Headquarters Location)
xCARE Inc. (Shibuya-ku, Tokyo)
Representative
Sho Fukunaga
Date of Establishment
January 31, 2022
Business Description
Building and supporting the execution of development projects on a specialized human resource platform for the pharmaceutical and medical device industries.
Homepage
Corporate: https://www.xcare-medical.com/campany/top/
Services: https://www.xcare-medical.com/
[Comment from Sho Fukunaga, CEO of xCARE Inc.]
I am deeply grateful for your continued support following the previous Pre-A round.
xCARE has grown into a platform with over 1,000 experts in Japan and over 1,000 overseas available for contract work, and many pharmaceutical and medical device manufacturers are utilizing these experts.
Our theme is to "change industry business practices." Previously, our industry had only two options: "hiring" or "full outsourcing." We aim to provide new options, such as incorporating contract workers as an alternative to hiring into our operations, allowing us to accumulate know-how and control while advancing highly fluid projects, or building operational structures for parts of organizational roles with contract workers.
Similar services (like SES) exist in other industries, including the IT industry. We also entrust contract workers with roles such as "marketing," "product development," and "inside sales." In particular, performance has dramatically improved by switching from outsourcing to contract workers for product development and inside sales. We want to expand this third new option in the pharmaceutical and medical device industry to companies that find "hiring risky," "uncertain about the future," or "unable to hire good talent," and contribute to the industry as a whole.
Chugin Financial Group, Inc.
Phone: 086-223-3110
Public Relations Center: Okajima (Ext. 2255)
Keywords:
FAQ
What problem does xCARE solve?
It solves the challenge of securing highly specialized talent in pharmaceutical and medical device development.
What are xCARE's strengths?
Its matching system utilizes a network of over 2,000 domestic and international experts and AI.
Who made this investment?
The Chugin Infinity Fund No. 3 made the investment.
What is xCARE's future outlook?
It aims to expand its expert network, develop overseas customers, and enhance its AI matching capabilities.
Who can use this platform?
Pharmaceutical companies, medical device manufacturers, bio-ventures, and academia can use it.